India's Biological Regulatory landscape is at an inflection point. The country that pioneered affordable Biosimilar access, built one of the world's largest vaccine manufacturing ecosystems, and established the framework for recombinant Biological...

The decision to enter the Indian market with an advanced Biological product should be made with a comprehensive regulatory strategy in place. India's multi-authority regulatory environment, distinct clinical data requirements, unique quality...

Recombinant Therapeutics and Monoclonal antibodies (mAbs) represent the fastest-growing and highest-value segment of the global Biological Medicines market. India's mAb market is expanding rapidly, driven by biosimilar development, originator launches, and the...

India occupies a unique position in the global vaccine ecosystem — simultaneously the world's largest vaccine manufacturer by volume (producing approximately 60% of the world's vaccines), a significant importer for specialised products,...

In Pharmaceutical development, time is capital. Every month of delay between trial design and first patient enrolled has a quantifiable cost - in direct operational expenditure, in foregone revenue from delayed commercialisation,...

The Common Technical Document (CTD) is the universal language of Pharmaceutical and Biological registration. Most global regulatory agencies, including the USFDA, EMA and PMDA accept the ICH CTD format with regional Module...

One of the most consequential strategic decisions for any global Biological product company entering India is whether to proceed as an importer or establish local manufacturing. This decision has profound implications for...

Time Is Money — And Preventable Delays Are Common India's Biological product approval timelines are frequently longer than companies anticipate. While CDSCO has made significant progress in recent years — introducing electronic...